专利检索 ap:("The U.S.A., as represented by the Secretary, Department of Health AND Human Services") AND inv:"Cindy Luongo" 第 1 页

1.

发明申请
RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES 审中-公开

公开(公告)号：US20200283740A1

公开(公告)日：2020-09-10

申请号：US16877277

申请日：2020-05-18

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Peter L. Collins , Ursula J. Buchholz , Cindy Luongo

IPC分类号： C12N7/00 , A61K39/12 , C07K14/005 , A61K39/155

摘要： Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.

2.

发明公开
RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE 审中-公开

公开(公告)号：US20240197861A1

公开(公告)日：2024-06-20

申请号：US18555137

申请日：2022-04-27

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Ursula J. Buchholz , Shirin Munir , Cyril Le Nouen , Xueqiao Liu , Cindy Luongo , Peter L. Collins

IPC分类号： A61K39/215 , A61K39/00 , A61K39/155 , A61P31/14 , A61P37/04 , C07K14/005 , C12N15/86

CPC分类号： A61K39/215 , A61K39/155 , A61P31/14 , A61P37/04 , C07K14/005 , C12N15/86 , A61K2039/5256 , A61K2039/543 , A61K2039/55 , C12N2760/18622 , C12N2760/18634 , C12N2760/18644 , C12N2760/18671 , C12N2770/20022 , C12N2770/20034 , C12N2770/20071

摘要： Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing a recombinant Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike (S) protein as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the recombinant SARS-COV-2 S protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to SARS-COV-2 and HPIV3 in a subject.